[A21-49] Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 21.10.2021
Project no.:
A21-49
Commission:
Commission awarded on 29.04.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with treatment-naive advanced renal cell carcinoma
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2021-08-02.
| Project no. | Title | Status |
|---|---|---|
| G21-20 | Cabozantinib (thyroid carcinoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision) | Commission completed |
| A21-119 | Cabozantinib (renal cell carcinoma) - Addendum to Commission A21-49 | Commission completed |
| G21-27 | Cabozantinib (renal cell carcinoma) - Addendum to Commission A21-49 | Commission completed |
| A22-59 | Cabozantinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-10-21 A G-BA decision was published.